1Dal Ben D,Palumbo M,Zagotto G,et al.DNA topoisomerase Ⅱ structures and anthracycline activity:insights into ternary complex formation[J].Curr Pharm Des,2007,13(27):2766-80.
2Luo X,Evrovsky Y,Cole D,et al.Doxorubicin-induced acute changes in cytotoxic aldehydes,antioxidant status and cardiac function in the rat[J].Biochim Biophys Acta,1997,1360(1):45-52.
3Cole MP,Chaiswing L,Oberley TD,et al.The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity[J].Cardiovasc Res,2006,69(1):186-197.
4Deng S,Kruger A,Schmidt A,et al.Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice[J].Naunyn Schmiedebergs Arch Pharmacol,2009,380(1):25-34.
5Keizer HG,Pinedo HM,Schuurhuis G J,et al.Doxorubicin (adriamycin):a critical review of free radical-dependent mechanisms of cytotoxicity[J].Pharmacol Ther,1990,47(2):219-231.
6Simunek T,Sterba M,Popelova O,et al.Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone[J].Br J Pharmacol,2008,155(1):138-148.
7Kaiserova Iq,Simunek T,Sterba M,et al.New iron chelators in anthracycline-induced cardiotoxicity[J].Cardiovasc Toxicol,2007,7(2):145-150.
8Herman EH,Zhang J,Hasinoff BB,et al.Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (Ⅲ) displacement reactions of ICRF-187 and other bisdiketopiperazines[I].Cancer Chemother Pharmcol,1997,40(5):400-408.
10Eidenschink AB,Schroter G,Muller-Weihrich S,et al.Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood[J].Cardiol Young,2000,10(6):610-617.
